DrugPatentWatch Database Preview
Investigational Drug Information for Laquinimod
Email this page to a colleague
What is the development status for investigational drug Laquinimod?
Laquinimod is an investigational drug.
There have been 16 clinical trials for Laquinimod.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 13th 2007.
The most common disease conditions in clinical trials are Multiple Sclerosis, Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. The leading clinical trial sponsors are Teva Pharmaceutical Industries, Teva Branded Pharmaceutical Products R&D, Inc., and Teva Pharmaceutical Industries, Ltd.
Summary for Laquinimod
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,640 |
| WIPO Patent Applications | 525 |
| Japanese Patent Applications | 300 |
| Clinical Trial Progress | Phase 3 (2007-11-13) |
| Vendors | 96 |
Recent Clinical Trials for Laquinimod
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Laquinimod Eye-drops in Healthy Participants | Active Biotech AB | Phase 1 |
| A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo | Teva Pharmaceutical Industries | Phase 2 |
Clinical Trial Summary for Laquinimod
Top disease conditions for Laquinimod
Top clinical trial sponsors for Laquinimod
US Patents for Laquinimod
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
